iOnctura

Share on: 
Website: iOnctura
Description: 

Onctura’s pipeline contains an exquisitely selective PI3Kδ small molecule inhibitor which has just entered a phase I clinical trial in solid tumours, a second generation selective ATX small molecule inhibitor that is in IND enabling studies and an early preclinical phase anti-CD73 antibody program.

Career Page(s): 
Location(s): 
Genève
Switzerland